- Home
- FRME vs SUPN Comparison
FRME vs SUPN Comparison
Compare FRME & SUPN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | FRME | SUPN |
|---|---|---|
| Founded | 1893 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.2B | 2.9B |
| IPO Year | N/A | 2012 |
Fundamental Metrics
Financial Performance| Metric | FRME | SUPN |
|---|---|---|
| Price | $38.34 | $49.24 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 5 |
| Target Price | $47.33 | ★ $61.60 |
| AVG Volume (30 Days) | 287.0K | ★ 599.9K |
| Earning Date | 01-29-2026 | 02-24-2026 |
| Dividend Yield | ★ 3.77% | N/A |
| EPS Growth | ★ 32.99 | N/A |
| EPS | ★ 4.00 | N/A |
| Revenue | $649,589,000.00 | ★ $681,539,000.00 |
| Revenue This Year | $13.81 | $8.32 |
| Revenue Next Year | $14.43 | $23.36 |
| P/E Ratio | $9.54 | ★ N/A |
| Revenue Growth | ★ 9.53 | 4.54 |
| 52 Week Low | $33.13 | $29.16 |
| 52 Week High | $45.62 | $57.65 |
Technical Indicators
Market Signals| Indicator | FRME | SUPN |
|---|---|---|
| Relative Strength Index (RSI) | 55.93 | 52.20 |
| Support Level | $36.86 | $51.01 |
| Resistance Level | $38.69 | $52.30 |
| Average True Range (ATR) | 0.67 | 1.45 |
| MACD | -0.11 | -0.11 |
| Stochastic Oscillator | 58.77 | 40.00 |
Price Performance
Historical ComparisonAbout FRME First Merchants Corporation
First Merchants Corp, through its subsidiaries, provides its customers with financial services delivered locally by bankers. It offers personal banking, business banking, real estate mortgage lending, cash management services, brokerage, wealth management, and insurance. The company reports in only one segment which is community banking.
About SUPN Supernus Pharmaceuticals Inc.
Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. Its diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The company's products include Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, MYOBLOC, GOCOVRI, and Osmolex ER.